Cypress Capital Management (Wyoming)’s Edwards Lifesciences EW Stock Holding History

Cypress Capital Management (Wyoming)’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$70.6K	Hold	780	–	–	0.06%	93
2026 Q1	$62.5K	Hold	780	–	–	0.06%	84
2025 Q4	$66.5K	Sell	780 -50	-6%	-$4.1K	0.06%	78
2025 Q3	$64.5K	Hold	830	–	–	0.06%	81
2025 Q2	$64.9K	Hold	830	–	–	0.07%	79
2025 Q1	$60.2K	Hold	830	–	–	0.07%	77
2024 Q4	$61.4K	Hold	830	–	–	0.07%	74
2024 Q3	$54.8K	Sell	830 -125	-13%	-$9.08K	0.06%	78
2024 Q2	$88.2K	Hold	955	–	–	0.09%	66
2024 Q1	$91.3K	Hold	955	–	–	0.1%	60
2023 Q4	$72.8K	Hold	955	–	–	0.08%	66
2023 Q3	$66.2K	Hold	955	–	–	0.08%	65
2023 Q2	$90.1K	Hold	955	–	–	0.1%	58
2023 Q1	$79K	Hold	955	–	–	0.09%	62
2022 Q4	$71.3K	Sell	955 -750	-44%	-$57.8K	0.09%	62
2022 Q3	$141K	Hold	1,705	–	–	0.2%	42
2022 Q2	$162K	Hold	1,705	–	–	0.21%	41
2022 Q1	$201K	Hold	1,705	–	–	0.24%	44
2021 Q4	$221K	Sell	1,705 -2,025	-54%	-$236K	0.19%	68
2021 Q3	$422K	Hold	3,730	–	–	0.35%	50
2021 Q2	$386K	Hold	3,730	–	–	0.3%	58
2021 Q1	$312K	Sell	3,730 -30,918	-89%	-$2.61M	0.27%	64
2020 Q4	$3.16M	Sell	34,648 -30,860	-47%	-$2.56M	2.74%	5
2020 Q3	$5.5M	Sell	65,508 -490	-0.7%	-$38.2K	4.94%	3
2020 Q2	$4.56M	Sell	65,998 -1,670	-2%	-$119K	4.56%	3
2020 Q1	$4.25M	Sell	67,668 -4,518	-6%	-$326K	5.99%	3
2019 Q4	$5.61M	Buy	+72,186	New	+$5.64M	5.3%	3
2018 Q3	–	Sell	-35,925	Closed	-$1.74M	–	348
2018 Q2	$1.74M	Buy	+35,925	New	+$1.68M	1.83%	13
2017 Q3	–	Sell	-7,935	Closed	-$313K	–	273
2017 Q2	$313K	Buy	+7,935	New	+$290K	0.36%	53

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Cypress Capital Management (Wyoming)'s EW Position: Q2 2026 in Review

Cypress Capital Management (Wyoming) held its Edwards Lifesciences (EW) position steady in Q2 2026 at 780 shares worth $70.6K. The position accounts for 0.06% of the portfolio, ranked #93.

Cypress Capital Management (Wyoming) first reported a position in EW in Q2 2017 and has held it in 29 quarters since. The position peaked at $5.61M in Q4 2019. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Cypress Capital Management (Wyoming) held 780 shares of Edwards Lifesciences worth $70.6K as of Q2 2026.
Cypress Capital Management (Wyoming) left its Edwards Lifesciences share count unchanged in Q2 2026.
Edwards Lifesciences made up 0.06% of Cypress Capital Management (Wyoming)'s portfolio in Q2 2026, its #93 holding.
Cypress Capital Management (Wyoming) first reported a position in Edwards Lifesciences in Q2 2017 and has held it in 29 quarters since.
Cypress Capital Management (Wyoming)'s Edwards Lifesciences position peaked at $5.61M in Q4 2019.
1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q2 2026, filed 6 Aug 2026.